Etentamig in Heavily Pretreated Myeloma: Phase 3 CERVINO Results | IMS 2026 #myeloma

Daejin Abidoye, MD, of AbbVie discusses phase 3 CERVINO trial results for etentamig, a BCMA-targeting bispecific antibody, at IMS 2026 in Glasgow. He explains how T-cell engagers connect the immune system to myeloma cells, and describes the trial's heavily pretreated, triple-class exposed patients. Early results showed improved response rates and progression-free survival, with lower rates of infection, CRS and neurotoxicity than typical for this class. Overall survival data are still early.

Disclosure: Dr. Abidoye is an employee of AbbVie, the company developing etentamig.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction
0:35 What is a T-cell engager?
1:24 The CERVINO phase 3 trial
2:10 Efficacy results
2:51 Safety: lower infections, CRS and ICANS
3:54 Looking ahead: trispecifics